Compositions capable of facilitating penetration across a biological barrier
View Patent ↗This invention relates to novel penetrating compositions including one or more effectors included within a water soluble composition, immersed in a hydrophobic medium The invention also relates to methods of treating or preventing diseases by administering such penetrating compositions to affected subjects.
1. A method for producing an oral administration composition, the method comprising:
(i) providing a therapeutically effective amount of at least one effector in an aqueous composition, wherein said aqueous composition comprises a fatty acid salt selected from: sodium octanoate, sodium decanoate, sodium dodecanoate, and combinations thereof and wherein said effector comprises a peptide;
(ii) evaporating the aqueous composition by lyophilizing said aqueous composition to produce a lyophilizate comprising a water soluble composition comprising the fatty acid salt;
(iii) suspending the lyophilizate comprising a water soluble composition comprising the fatty acid salt in a hydrophobic medium to produce a suspension, wherein said hydrophobic medium is selected from the group consisting of aliphatic molecules, cyclic molecules, aromatic molecules and combinations thereof; and
(iv) further comprising a lecithin, a bile salt or a non-ionic detergent.
2. The method of claim 1 , wherein said at least one peptide effector comprises an impermeable molecule selected from the group consisting of: insulin; erythropoietin (EPO); glucagon-like peptide 1 (GLP-1); melanocyte stimulating hormone (αMSH); parathyroid hormone (PTH); peptide YY amino acids 3-36 (PYY(3-36)); interleukin-2 (IL-2); a 1-antitrypsin; granulocyte/monocyte colony stimulating factor (GM-CSF); granulocyte colony stimulating factor (G-CSF); T20; anti-TNF antibodies; interferon α; interferon β; interferon γ; luteinizing hormone releasing hormone (LHRH) analog; brain-derived natriuretic peptide (BNP); a hormone; a growth factor; an incretin; a neurotrophic factor; an antibody; a monoclonal antibody; an antibody fragment; an immunomodulator; a soluble receptor; an enzyme; and Caspofungin.
3. The method of claim 1 , wherein said fatty acid salt is sodium octanoate.
4. The method of claim 1 , wherein said aliphatic molecules are selected from the group consisting of: mineral oil, paraffin, fatty acids, mono-glycerides, di-glycerides, tri-glycerides, such as long chain triglycerides, medium chain triglycerides, short chain triglycerides, ethers, and esters, wherein said cyclic hydrophobic medium is selected from the group consisting of: terpenoids, cholesterol, cholesterol derivatives such as cholesterol sulfate, and cholesterol esters of fatty acids, or wherein said aromatic hydrophobic medium is benzyl benzoate.
5. The method of claim 4 , wherein said aliphatic molecules are medium chain triglycerides.
6. The method of claim 4 , wherein said long chain triglyceride is castor oil.
7. The method of claim 4 , wherein said short chain triglyceride is glyceryl tributyrate.
8. The method of claim 1 , wherein said water soluble composition further comprises a stabilizer.
9. The method of claim 8 , wherein said water soluble composition further comprises polyvinylpyrrolidone.
10. The method of claim 8 , wherein said water soluble composition further comprises polyvinylalcohol.
11. The method of claim 1 , wherein said at least one peptide effector comprises an impermeable molecule selected from the group consisting of: parathyroid hormone amino acids 1-34 (PTH 1-34); growth hormone; calcitonin; luteinizing hormone (LH); follicle-stimulating hormone (FSH); enkephalin; dalargin; kytotorphin; basic fibroblast growth factor (bFGF); hirudin and hirulog.
12. An oral administration composition obtained by the method of claim 1 , the composition comprising:
(i) a therapeutically effective amount of at least one effector in an aqueous composition, wherein said aqueous composition comprises a fatty acid salt selected from: sodium octanoate, sodium decanoate, sodium dodecanoate, and combinations thereof, and wherein said effector comprises a peptide;
(ii) a lyophilizate comprising a water soluble composition comprising the fatty acid salt;
(iii) a hydrophobic medium, wherein said hydrophobic medium is selected from the group consisting of aliphatic molecules, cyclic molecules, aromatic molecules and combinations thereof; and
(iv) a lecithin, a bile salt or a non-ionic detergent.
13. The therapeutic composition of claim 12 , comprising a non-ionic detergent.
14. The therapeutic composition of claim 13 , wherein the non-ionic detergent is a cremophore, a polyethylene glycol fatty alcohol ether, Solutol HS15, a poloxamer or a sorbitan fatty acid ester.
15. The therapeutic composition of claim 14 , wherein the non-ionic detergent is a sorbitan fatty acid ester.
16. The therapeutic composition of claim 12 , wherein the composition further comprises a monoglyceride.
17. The therapeutic composition of claim 16 , wherein the monoglyceride is glyceryl monooctanoate.
18. The therapeutic composition of claim 12 , which further comprises an alcohol selected from the group consisting of linear alcohols, branched alcohols, cyclical alcohols, aromatic alchohols and combinations thereof.
19. The therapeutic composition of claim 12 , wherein said composition is contained within a capsule.
20. The therapeutic composition of claim 12 , wherein said composition is in the form of a tablet.
21. The therapeutic composition of claim 12 , further comprising a pharmaceutically acceptable excipient, a pharmaceutically acceptable carrier, or combinations thereof.
22. The therapeutic composition of claim 16 , wherein the monoglyceride is glyceryl monooctanoate, glyceryl monodecanoate, glyceryl monolaurate, glyceryl monomyristate, glyceryl monostearate, glyceryl monopalmitate or glyceryl monooleate.